MAPT and Alzheimer disease: The Mild-AD group also exhibited significantly higher hNEX hyper-phosphorylated tau (p-tau (S202, T205)) (AMC, 1.00 ± 0.09; MCI, 0.81 ± 0.14; Mild-AD, 1.91 ± 0.16, p < 0.05 vs. AMC, p < 0.01 vs. MCI, Figure S7C) and p-tau (T181) (AMC, 1.00 ± 0.17; MCI, 1.22 ± 0.23; Mild-AD, 2.66 ± 0.33, p < 0.01 vs. AMC, p < 0.05 vs. MCI, Figure S7D), while hNEX p-tau (T231) did not differ between groups (AMC, 1.00 ± 0.10; MCI, 1.30 ± 0.16; Mild-AD, 1.12 ± 0.16, p < 0.01, Figure S7E).